$LSTA
LISATA THERAPEUTICS, INC.

2021 Form 10-K Financial Statement

#000032001722000016 Filed on March 22, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.37M $2.540M $9.892M
YoY Change 14.94% 9.48% 6.42%
% of Gross Profit
Research & Development $17.68M $2.910M $9.253M
YoY Change 91.07% 5.05% -14.3%
% of Gross Profit
Depreciation & Amortization $100.0K $10.00K $100.0K
YoY Change 0.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $29.05M $5.450M $19.15M
YoY Change 51.74% 7.28% -4.71%
Operating Profit -$29.05M -$19.15M
YoY Change 51.74% -4.71%
Interest Expense $151.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $76.00K $10.00K $132.0K
YoY Change -42.42% -92.31% -82.16%
Pretax Income -$28.97M -$5.430M -$19.01M
YoY Change 52.39% 9.7% -1.75%
Income Tax -$1.508M $0.00 -$10.87M
% Of Pretax Income
Net Earnings -$27.47M -$5.430M -$8.150M
YoY Change 237.01% 9.48% -57.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.50 -$0.53
Diluted Earnings Per Share -$0.50 -$279.8K -$0.53
COMMON SHARES
Basic Shares Outstanding 55.31M shares 19.40M shares 15.44M shares
Diluted Shares Outstanding 55.31M shares 15.44M shares

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.97M $34.57M $34.60M
YoY Change 174.48% 37.43% 37.3%
Cash & Equivalents $24.65M $16.51M $16.50M
Short-Term Investments $70.32M $18.06M $18.10M
Other Short-Term Assets $1.212M $800.0K $800.0K
YoY Change 51.5% 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $96.18M $35.33M $35.30M
YoY Change 172.47% 36.03% 35.77%
LONG-TERM ASSETS
Property, Plant & Equipment $786.0K $57.00K $600.0K
YoY Change 31.0% -43.0% -40.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.00K $614.0K $0.00
YoY Change -43.2% -100.0%
Total Long-Term Assets $826.0K $671.0K $700.0K
YoY Change 18.0% -43.18% -41.67%
TOTAL ASSETS
Total Short-Term Assets $96.18M $35.33M $35.30M
Total Long-Term Assets $826.0K $671.0K $700.0K
Total Assets $97.01M $36.00M $36.00M
YoY Change 169.47% 32.59% 32.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.934M $1.020M $1.000M
YoY Change 93.4% -31.54% -33.33%
Accrued Expenses $2.589M $2.486M $2.500M
YoY Change 3.56% -44.58% -44.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.523M $3.506M $3.500M
YoY Change 29.23% -41.33% -41.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $485.0K $254.0K $300.0K
YoY Change 61.67% -59.29% -50.0%
Total Long-Term Liabilities $485.0K $254.0K $300.0K
YoY Change 61.67% -59.29% -50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.523M $3.506M $3.500M
Total Long-Term Liabilities $485.0K $254.0K $300.0K
Total Liabilities $4.754M $3.760M $3.500M
YoY Change 35.83% -43.03% -44.44%
SHAREHOLDERS EQUITY
Retained Earnings -$425.6M
YoY Change 1.95%
Common Stock $19.00K
YoY Change 72.73%
Preferred Stock
YoY Change
Treasury Stock (at cost) $708.0K
YoY Change 0.0%
Treasury Stock Shares 11.08K shares
Shareholders Equity $92.25M $32.50M $32.50M
YoY Change
Total Liabilities & Shareholders Equity $97.01M $36.00M $36.00M
YoY Change 169.47% 32.59% 32.35%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$27.47M -$5.430M -$8.150M
YoY Change 237.01% 9.48% -57.91%
Depreciation, Depletion And Amortization $100.0K $10.00K $100.0K
YoY Change 0.0% -50.0% 0.0%
Cash From Operating Activities -$22.25M -$5.560M -$8.823M
YoY Change 152.13% 31.75% -53.27%
INVESTING ACTIVITIES
Capital Expenditures $60.00K -$10.00K $20.00K
YoY Change 200.0%
Acquisitions
YoY Change
Other Investing Activities -$54.84M $910.0K -$7.260M
YoY Change 655.32% -82.83% -133.88%
Cash From Investing Activities -$54.90M $910.0K -$7.277M
YoY Change 654.38% -82.83% -133.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $85.50M $18.73M
YoY Change 356.54%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $85.28M 10.00K $18.58M
YoY Change 358.97% -96.3% 1470.58%
NET CHANGE
Cash From Operating Activities -$22.25M -5.560M -$8.823M
Cash From Investing Activities -$54.90M 910.0K -$7.277M
Cash From Financing Activities $85.28M 10.00K $18.58M
Net Change In Cash $8.135M -4.640M $2.480M
YoY Change 228.02% -443.7% -33.57%
FREE CASH FLOW
Cash From Operating Activities -$22.25M -$5.560M -$8.823M
Capital Expenditures $60.00K -$10.00K $20.00K
Free Cash Flow -$22.31M -$5.550M -$8.843M
YoY Change 152.23% 31.52% -53.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000320017
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-33650
CY2021 dei Entity Registrant Name
EntityRegistrantName
CALADRIUS BIOSCIENCES, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2343568
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
110 Allen Road, 2nd Floor
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Basking Ridge
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07920
CY2021 dei City Area Code
CityAreaCode
908
CY2021 dei Local Phone Number
LocalPhoneNumber
842-0100
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
CLBS
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
95000000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60533064 shares
CY2021 dei Auditor Firm
AuditorFirmId
248
CY2021 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2021 dei Auditor Location
AuditorLocation
New York, New York
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24647000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16512000 USD
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
70323000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
18061000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1212000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
758000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
96182000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35331000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
764000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
614000 USD
CY2021Q4 us-gaap Assets
Assets
97008000 USD
CY2020Q4 us-gaap Assets
Assets
36002000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1934000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1020000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2589000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2486000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4523000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3506000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
485000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
254000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
5008000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
3760000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2020Q4 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2020Q4 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59800792 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19389413 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59789712 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19378333 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
60000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
545988000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458748000 USD
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453016000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-425550000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-70000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
92254000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32496000 USD
CY2021Q4 us-gaap Minority Interest
MinorityInterest
-254000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-254000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
92000000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32242000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97008000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36002000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17680000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9253000 USD
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11370000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9892000 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
29050000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
19145000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-29050000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19145000 USD
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
151000 USD
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
132000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-75000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
76000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
132000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28974000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19013000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1508000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10872000 USD
CY2021 us-gaap Profit Loss
ProfitLoss
-27466000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
-8141000 USD
CY2021 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0 USD
CY2020 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
9000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27466000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8150000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55313000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55313000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15440000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15440000 shares
CY2021 us-gaap Profit Loss
ProfitLoss
-27466000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
-8141000 USD
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-57000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-57000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-27523000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8156000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2020 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
9000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27523000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8165000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20553000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
-8141000 USD
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-15000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1117000 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18728000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32242000 USD
CY2021 us-gaap Profit Loss
ProfitLoss
-27466000 USD
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-57000 USD
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1757000 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
85500000 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
92000000 USD
CY2021 us-gaap Profit Loss
ProfitLoss
-27466000 USD
CY2020 us-gaap Profit Loss
ProfitLoss
-8141000 USD
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2005000 USD
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1265000 USD
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
55000 USD
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
63000 USD
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2514000 USD
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-307000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
453000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-56000 USD
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
150000 USD
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-466000 USD
CY2021 clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
1250000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2020 clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-2839000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22245000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8823000 USD
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
179775000 USD
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34799000 USD
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
124939000 USD
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27542000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54896000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7277000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000 USD
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
248000 USD
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
148000 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
85500000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18728000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
85276000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18580000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8135000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2480000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16512000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14032000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24647000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16512000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div>
CY2021 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div>
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
91522000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
70000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
91452000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
30750000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
30737000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
91452000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
30737000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
91522000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
91452000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
30750000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
30737000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
91522000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
91452000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
30750000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
30737000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
430000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
370000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
368000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
313000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000 USD
CY2021 us-gaap Depreciation
Depreciation
100000 USD
CY2020 us-gaap Depreciation
Depreciation
100000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
574000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
2034000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
1716000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
326000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400000 USD
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2589000 USD
CY2020Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2486000 USD
CY2021Q4 clbs Number Of Offices Under Operating Leases
NumberOfOfficesUnderOperatingLeases
2 office
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
724000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
574000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
724000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
485000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
254000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
714000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
624000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09625
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
286000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
217000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
190000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
143000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
836000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
122000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
714000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65000000 USD
CY2021Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
801148 shares
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1800000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
963700 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.64
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M9D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2020Q4 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
2638355 shares
CY2020Q4 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.18
CY2020 clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y11M23D
CY2020Q4 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1314790 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.32
CY2021 clbs Warrants Granted
WarrantsGranted
19519393 shares
CY2021 clbs Weighted Average Exercise Price Warrants Granted
WeightedAverageExercisePriceWarrantsGranted
2.90
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7250 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.28
CY2021 clbs Aggregate Intrinsic Value Option Exercised
AggregateIntrinsicValueOptionExercised
3000 USD
CY2021 clbs Warrants Exercised
WarrantsExercised
801148 shares
CY2021 clbs Weighted Average Exercise Price Warrants Exercised
WeightedAverageExercisePriceWarrantsExercised
2.19
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29842 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.18
CY2021 clbs Warrants Canceled
WarrantsCanceled
0 shares
CY2021 clbs Weighted Average Exercise Price Warrants Canceled
WeightedAverageExercisePriceWarrantsCanceled
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
109549 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
34.12
CY2021 clbs Warrants Expired
WarrantsExpired
0 shares
CY2021 clbs Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2131849 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.64
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2021Q4 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
21356600 shares
CY2021Q4 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.84
CY2021 clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y4M13D
CY2021Q4 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2120643 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.66
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M15D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2021Q4 clbs Sharesvestedandexpectedtovest
Sharesvestedandexpectedtovest
21356600 shares
CY2021Q4 clbs Weighted Average Exercise Price Warrants Vested And Expected To Vest
WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
2.84
CY2021 clbs Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest
WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
P4Y4M13D
CY2021Q4 clbs Aggregate Intrinsic Value Warrantsvestedandexpectedtovest
AggregateIntrinsicValueWarrantsvestedandexpectedtovest
0 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1122783 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
9.26
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 USD
CY2021Q4 clbs Warrants Vested
WarrantsVested
21356600 shares
CY2021Q4 clbs Weighted Average Exercise Price Warrants Exercisable
WeightedAverageExercisePriceWarrantsExercisable
2.84
CY2021 clbs Weighted Average Remaining Contractual Termwarrantsvested
WeightedAverageRemainingContractualTermwarrantsvested
P4Y4M13D
CY2021Q4 clbs Aggregate Intrinsic Value Warrantsvested
AggregateIntrinsicValueWarrantsvested
0 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2005000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1265000 USD
CY2017Q1 us-gaap Grants Receivable
GrantsReceivable
12200000 USD
CY2017Q1 clbs Funding Amount Awarded
FundingAmountAwarded
8600000 USD
clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
8200000 USD
CY2017Q2 clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
5700000 USD
CY2017Q4 clbs Milestone Payment On Grant Award Cash Received
MilestonePaymentOnGrantAwardCashReceived
1900000 USD
CY2018Q1 clbs Progress Payment On Grant Award Cash Received
ProgressPaymentOnGrantAwardCashReceived
300000 USD
CY2019Q2 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
200000 USD
CY2020Q3 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
46000 USD
CY2021 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
0 USD
CY2020 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
1600000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28974000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19013000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28974000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19013000 USD
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1508000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-10872000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1508000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10872000 USD
CY2021 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0 USD
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0 USD
CY2021 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-1508000 USD
CY2020 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-10872000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1508000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10872000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6085000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3993000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
320000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
5000 USD
CY2021 clbs Effective Income Tax Rate Reconciliation Changein State Deferred Amount
EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount
622000 USD
CY2020 clbs Effective Income Tax Rate Reconciliation Changein State Deferred Amount
EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount
5122000 USD
CY2021 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
2277000 USD
CY2020 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
0 USD
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1407000 USD
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
387000 USD
CY2021 clbs Effective Income Tax Rate Reconciliation Section382 Nol Limitation Amount
EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount
35438000 USD
CY2020 clbs Effective Income Tax Rate Reconciliation Section382 Nol Limitation Amount
EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount
0 USD
CY2021 clbs Effective Income Tax Rate Reconciliation Sale Of State Net Operating Losses
EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses
-1508000 USD
CY2020 clbs Effective Income Tax Rate Reconciliation Sale Of State Net Operating Losses
EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses
-10872000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-33979000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1521000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1508000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10872000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36281000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
68286000 USD
CY2021Q4 clbs Deferred Tax Assets Right Of Use Liability
DeferredTaxAssetsRightOfUseLiability
201000 USD
CY2020Q4 clbs Deferred Tax Assets Right Of Use Liability
DeferredTaxAssetsRightOfUseLiability
176000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3086000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5025000 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
97000 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
131000 USD
CY2021Q4 clbs Deferred Tax Assets Accumulated Depreciation
DeferredTaxAssetsAccumulatedDepreciation
26000 USD
CY2020Q4 clbs Deferred Tax Assets Accumulated Depreciation
DeferredTaxAssetsAccumulatedDepreciation
19000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
176000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
167000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
526000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
526000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40393000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
74330000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
204000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
161000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
204000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
161000 USD
CY2021Q4 clbs Net Deferred Tax Assets And Liabilities Gross
NetDeferredTaxAssetsAndLiabilitiesGross
40189000 USD
CY2020Q4 clbs Net Deferred Tax Assets And Liabilities Gross
NetDeferredTaxAssetsAndLiabilitiesGross
74169000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40189000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
74169000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021Q4 clbs Operating Loss Carryforwards Annual Available Five Years Net Unrealized Built In Gain
OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain
1100000 USD
CY2021Q2 clbs Proceeds From Sale Of Net Operating Losses Njeda Program
ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
1400000 USD
CY2021Q2 clbs Proceeds From Sale Of Net Operating Losses Njeda Program Gross
ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
1500000 USD
CY2021Q2 clbs Loss On Sale Of Net Operating Losses
LossOnSaleOfNetOperatingLosses
100000 USD

Files In Submission

Name View Source Status
0000320017-22-000016-index-headers.html Edgar Link pending
0000320017-22-000016-index.html Edgar Link pending
0000320017-22-000016.txt Edgar Link pending
0000320017-22-000016-xbrl.zip Edgar Link pending
clbs-20211231.htm Edgar Link pending
clbs-20211231.xsd Edgar Link pending
clbs-20211231_cal.xml Edgar Link unprocessable
clbs-20211231_def.xml Edgar Link unprocessable
clbs-20211231_htm.xml Edgar Link completed
clbs-20211231_lab.xml Edgar Link unprocessable
clbs-20211231_pre.xml Edgar Link unprocessable
clbs-ex311_20211231xq4.htm Edgar Link pending
clbs-ex32_20211231.htm Edgar Link pending
exh23120211231.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending